GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rang în acțiuni
#3640
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Preț acțiune
$27.73
Capitalizare de piață
$4.70B
Schimbare (1 zi)
0.71%
Schimbare (1 an)
-11.52%
Țară
IN
Tranzacționează GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Categorie
Healthcare
Raport P/B pentru GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Raport P/B la data de October 2026 TTM: 18.70
Conform celor mai recente rapoarte financiare și prețului acțiunilor GlaxoSmithKline Pharmaceuticals Limited, raportul P/B actual (TTM) este 18.70. La sfârșitul anului 2024, compania avea un P/B de 18.93.
Istoricul raportului P/B pentru GlaxoSmithKline Pharmaceuticals Limited din 2004 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 18.70 | -23.00% |
| 2025 | 24.29 | 28.30% |
| 2024 | 18.93 | 46.87% |
| 2023 | 12.89 | 21.54% |
| 2022 | 10.60 | -35.77% |
| 2021 | 16.51 | 41.12% |
| 2020 | 11.70 | 13.72% |
| 2019 | 10.29 | 18.79% |
| 2018 | 8.66 | -25.23% |
| 2017 | 11.58 | -39.20% |
| 2016 | 19.05 | 60.47% |
| 2015 | 11.87 | -7.01% |
| 2013 | 12.77 | 39.51% |
| 2012 | 9.15 | 7.51% |
| 2011 | 8.51 | -16.10% |
| 2010 | 10.15 | 32.71% |
| 2009 | 7.64 | 23.58% |
| 2008 | 6.19 | -1.82% |
| 2007 | 6.30 | -22.76% |
| 2006 | 8.16 | -19.22% |
| 2005 | 10.10 | 38.74% |
| 2004 | 7.28 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 31.9092 | 70.60% |
US
|
|
| 7.3138 | -60.90% |
US
|
|
| -84.6033 | -552.32% |
US
|
|
| 8.6873 | -53.56% |
US
|
|
| 8.4776 | -54.68% |
CH
|
